

FROM W&C LLP 19TH FL.

(MON) 8. 28' 06 12:05/ST. 12:03/NO. 4260454869 P 7

USSN 10/506,345

Atty. Docket No. 1103326-0777

Page 7 of 11

RECEIVED  
CENTRAL FAX CENTER

AUG 28 2006

**Amendments to the Specification**

**Abstract:** Applicant submits herewith an abstract on a separate sheet as part of this response. The abstract is found at the end of this paper.

**Replace the paragraph [0034] appearing at page 4, lines 9-10 with the following replacement paragraph:**

In a further aspect of the invention, the  $\text{NHR}_1\text{R}_2\text{R}_3^+$  salt of omeprazole or esomeprazole has a pKa value being equal to or above 10. More preferred is a pKa value of equal to or above 10.5